calcimedica is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune disorders, organ transplant rejection, and other immune diseases.
Company profile
Ticker
CALC
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CalciMedica, Inc. /DE/, GRAYBUG LLC, GRAYBUG VISION, INC., GRAYBUG, Inc.
SEC CIK
Corporate docs
IRS number
452120079
CALC stock data
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
10 Apr 24
8-K
Other Events
29 Mar 24
424B5
Prospectus supplement for primary offering
29 Mar 24
S-8
Registration of securities for employees
28 Mar 24
8-K
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
28 Mar 24
8-K
Regulation FD Disclosure
13 Feb 24
EFFECT
Notice of effectiveness
12 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
UPLOAD
Letter from SEC
6 Feb 24
S-3
Shelf registration
31 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
35.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 1.55 bn |
Total shares | 3.78 mm |
Total puts | 0.00 |
Total calls | 36.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BML Investment Partners | 1.24 mm | $921.00 k |
Valence Investments SPV VI | 860.98 k | $4.74 mm |
Leerink Revelation Healthcare Fund I | 542.03 k | $2.98 mm |
Orbimed Advisors | 297.38 k | $790.88 mm |
Flynn James E | 276.80 k | $830.00 k |
CVF 2018 | 272.98 k | $500.00 k |
Hudson Bay Capital Management | 166.86 k | $432.16 mm |
BML Capital Management | 88.78 k | $236.11 mm |
Geode Capital Management | 13.35 k | $34.59 mm |
First Manhattan | 13.23 k | $35.17 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Eric W Roberts | Common Stock | Buy | Acquire P | Yes | No | 3.9 | 3,254 | 12.69 k | 39,894 |
1 Apr 24 | Eric W Roberts | Common Stock | Buy | Acquire P | Yes | No | 3.9 | 746 | 2.91 k | 36,640 |
28 Mar 24 | A. Rachel Leheny | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.16 | 115,000 | 478.40 k | 115,000 |
28 Mar 24 | Sudarshan Hebbar | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.16 | 82,500 | 343.20 k | 82,500 |
28 Mar 24 | Eric W Roberts | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.16 | 77,500 | 322.40 k | 77,500 |
28 Mar 24 | Kenneth A. Stauderman | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.16 | 62,500 | 260.00 k | 62,500 |
News
CalciMedica Announces Last Patient Enrolled In Phase 2b CARPO Trial Of Auxora In Acute Pancreatitis; Full Target Enrollment Of 216 Patients Achieved
24 Apr 24
CalciMedica And 2 Other Penny Stocks Insiders Are Buying
3 Apr 24
HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $20 Price Target
1 Apr 24
CalciMedica Q4 EPS $(0.23)
28 Mar 24
HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $20 Price Target
13 Mar 24
Press releases
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
28 Mar 24
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
13 Mar 24
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
28 Feb 24
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
13 Feb 24